Eiger BioPharmaceuticals Inc logo

EIGR

Eiger BioPharmaceuticals Inc

$9.32

Earnings Summary

Revenue
$4.09Mn
Net Profits
$-21.88Mn
Net Profit Margins
-534.93%

Highlights

Revenue:

Eiger BioPharmaceuticals Inc’s revenue jumped 95.09% since last year same period to $4.09Mn in the Q2 2022. On a quarterly growth basis, Eiger BioPharmaceuticals Inc has generated 53.05% jump in its revenue since last 3-months.

Net Profits:

Eiger BioPharmaceuticals Inc’s net profit fell -14.13% since last year same period to $-21.88Mn in the Q2 2022. On a quarterly growth basis, Eiger BioPharmaceuticals Inc has generated 3.35% jump in its net profits since last 3-months.

Net Profit Margins:

Eiger BioPharmaceuticals Inc’s net profit margin jumped 41.5% since last year same period to -534.93% in the Q2 2022. On a quarterly growth basis, Eiger BioPharmaceuticals Inc has generated 36.85% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Eiger BioPharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.61
EPS Estimate Current Year
-0.61

Highlights

EPS Estimate Current Quarter:

Eiger BioPharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.61 - a 4.69% jump from last quarter’s estimates.

EPS Estimate Current Year:

Eiger BioPharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.61.

Key Ratios

Key ratios of the Eiger BioPharmaceuticals Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.33
Return on Equity (ROE)
-0.83
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Eiger BioPharmaceuticals Inc’s return on assets (ROA) stands at -0.33.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Eiger BioPharmaceuticals Inc’s return on equity (ROE) stands at -0.83.

Dividend Per Share (DPS):

Eiger BioPharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.64
-0.64
0%

Company Information

Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis.

Organisation
Eiger BioPharmaceuticals Inc
Headquarters
Palo Alto, California, US
Employees
28
Industry
Health Technology
CEO
Krisztina Zsebo